Transition to a Value-Based Healthcare system can put Greece back on the innovation map

Access to pharmaceutical innovation for patients is not solely a healthcare issue; it is simply a strategic indicator of resilience, κοινωνικά cohesion and economical dynamism, reflecting the grade to which a system tin respond to modern needs while ensuring sustainability and maturation prospects, according to Savvas Charalambidis, Vice President of PIF and General Manager of Gilead Sciences.

In Greece, this statement has present go a cardinal contented of nationalist wellness policy. The limits of the existing financing exemplary are evident, some successful terms of system functionality and successful narration to the timely and equitable entree of patients to innovative treatments.

Innovation cannot beryllium treated arsenic a fiscal variable oregon a outgo to beryllium contained. On the contrary, entree to innovation is impervious of a healthcare system’s maturity, reflecting not lone the prime of attraction but besides a country’s strategic presumption within the European concern landscape. Today, the main contented lies successful the structure of financing. The dense reliance connected mandatory rebates and clawbacks—which successful Greece transcend 70%—combined with an concern diminution of astir 20% implicit the past 5 years, has created an situation that does not let for stability oregon planning. The existent backing exemplary has reached its limits, with the deficiency of predictability acting arsenic a deterrent to innovation and semipermanent investment.

The representation becomes clearer when compared with different European systems. In countries such arsenic Belgium, reimbursement mechanisms are constricted to astir 4%, successful France to astir 6.6% (2023), while successful the United Kingdom they stand astatine astir 26.5%. Italy operates with a headdress connected pharmaceutical expenditure astatine 15.3% of total healthcare spending (2024), while adjacent markets such arsenic Romania (15–25%) are gradually introducing rationalisation measures. By contrast, Greece combines a precocious fiscal load with debased predictability, creating an situation that restricts entree and discourages concern successful innovative therapies and infrastructure.

The interaction is already measurable. According to EFPIA’s WAIT 2024 data, the availability of caller therapies successful Greece is astir 4% little than the European average, while delays successful diligent entree stay significant, straight affecting objective outcomes. At the aforesaid time, Greece is lagging successful attracting probe and improvement investment, with a declining trend successful objective trials during the 2023–2025 play and expanding outflow of technological talent abroad—an improvement that deprives the state of valuable quality capital.

The PhARMA Innovation Forum has repeatedly highlighted the request to transition to a antithetic pharmaceutical argumentation exemplary that links spending to value and diligent outcomes. A wide displacement towards a value-based healthcare system is required, where value is defined not by the volume of services provided, but by existent outcomes for patients. This transition is not a substance of argumentation choice, but a indispensable betterment with a wide improvement footprint, arsenic it is straight linked to the organisation and financing of the healthcare system.

The constitution of a balanced model of organization and societal co-responsibility is simply a cardinal prerequisite for the sustainability of the system.